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A B S T R A C T
Background: Vaccinia based immunizations have caused myo/pericarditis and vaccine study volunteers are
monitored by ECG. We report ECG outcome obtained during the screening period for an HIV vaccine trial.
Methods: ECG was performed in healthy Tanzanian volunteers. ECG abnormalities and ﬁndings interfering with
the interpretation of myo/pericarditis were subject to study ineligibility. We determined the prevalence of left
ventricular hypertrophy (LVH) deﬁned by the Sokolow-Lyon (SL) or the Cornell index, ST-elevations and early
repolarization (ERP) in association with gender, age, BMI and body height by regression analysis adjusted for
gender and age.
Results: In 257 volunteers (median age 23 years, 63% males) overall positivity for LVH deﬁned by SL or Cornell
criteria was seen in 20.6% and 3.5%, ST-elevations ≥0.1 mV or ≥0.2 mV in 77.8% and 38.1%, and ERP in
23.4%. Positive SL criteria were associated with male gender (PR 7.84, p < 0.001) and lower age (PR 0.70,
p= 0.002), and associated with increased body height and lower BMI in univariate analysis. Positive Cornell
criteria were only associated with lower age (PR 0.44, p= 0.010). ST-elevations≥0.2 mV were associated with
male gender (PR 8.05, p < 0.001) and lower age (PR 0.81, p= 0.003), and ERP with male gender (PR 2.86,
p < 0.001). Vaccine study ineligibility due to ECG ﬁndings was concluded in 22.1% of the screening
population.
Conclusions: High prevalence of LVH according to SL in association with ST-elevation and ERP is especially
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found in young and male Africans. ECG variations need to be considered for eligibility criteria in studies
investigating potential cardiotoxic agents in Africa.
1. Introduction
With changing lifestyles and increasing urbanization, cardiovascu-
lar disease is increasingly prevalent in sub-Saharan Africa [1]. Electro-
cardiogram (ECG) is a non-invasive, widely available tool to assess
heart disease. Yet, the reference ranges for a valid interpretation of ECG
tracings are derived from Caucasian populations and normal ranges for
ECG ﬁndings in African populations are not very well deﬁned [2,3,4],
though many large scale studies in North American populations have
pointed out diﬀerences in ECG ﬁndings between African Americans and
Caucasian Americans.
It has been described that voltages in ECG may be higher in
populations of African origin and ST changes are more frequent as
compared to Caucasian populations [5,6,7]. In this respect, left
ventricular hypertrophy (LVH) criteria that rely on left or right
precordial voltage such as the Sokolow Lyon (SL) Index have been
reported to be of low speciﬁcity favouring the Cornell criteria in African
populations [8,9,10,11,12]. Independent of ethnic heritage, ST-eleva-
tion characterized by an elevation of the QRS-ST junction (J point) has
been described to be present in up to 93% of young males [13,14].
Early repolarization (ERP) characterized by an ST-elevation of
≥0.1 mV in multiple leads, often associated with QRS notching or
slurring (J wave), is usually viewed as a benign abnormality in young
and asymptomatic individuals, but has been associated with an
increased risk for ventricular arrhythmias and sudden cardiac death
[15]. Frequencies of ERP in the context of ethnic background are
discussed controversially, with some reports indicating an overall
prevalence of 1–2% independent of race [16]. More recent reports
indicate higher prevalence in populations with African heritage as
compared to Caucasians [17,18,19].
Vaccinia virus based vaccines have been associated with myo/
pericarditis [20,21] and volunteers participating in Modiﬁed Vaccinia
Ankara (MVA) containing vaccine trials are usually ECG monitored for
safety [22]. We recently conducted the TaMoVac01 multicentre phase
II, MVA containing HIV vaccine trial in healthy volunteers from
Tanzania [23] and encountered challenges during eligibility assess-
ments due to high rates of abnormal ECG ﬁndings that could potentially
interfere with the diagnosis of suspected vaccine induced myo/peri-
carditis. In a post hoc analysis we here investigate frequencies and
factors associated with variable ECG ﬁndings in otherwise clinically
healthy young Tanzanian volunteers and the related implications for
MVA based vaccine studies.
2. Methods
2.1. Study settings and ethics statements
The study was conducted at the Muhimbili University of Health and
Allied Sciences (MUHAS) in Dar es Salaam, and the National Institute
for Medical Research (NIMR)-Mbeya Medical Research Center (MMRC)
in Mbeya. Ethical approval for TaMoVac01 was obtained from the
institutional review boards of the Muhimbili University of Health and
Allied Sciences and the Mbeya Medical Research Ethics Committee. The
Tanzania National Institute for Medical Research (NIMR), serving as the
National Ethics Committee, and the Swedish Ethics Committee also
approved the study. The study was conducted according to the
principles of International Conference of Harmonization and Good
Clinical Practice guidelines (ICH-GCP). All volunteers were provided
with an information sheet and informed consent was obtained before
any study procedures took place.
2.2. Study population and eligibility criteria
Volunteers for the TaMoVac 01 HIV vaccine trial were recruited
from the Police, Prison forces, and a youth clinic in Dar es Salaam, as
well as from the general population in Mbeya in Tanzania. Study
volunteers aged 18 years or older underwent screening including
medical history, complete physical examination, blood pressure and
pulse rate assessments, laboratory analyses (complete blood count, ALT,
direct and indirect bilirubin, random blood glucose and creatinine),
urine analysis, serology testing for HIV, syphilis and hepatitis B as well
as pregnancy testing in females. A 12-lead ECG was recorded during
screening in order to exclude volunteers with evidence of cardiac
disease and those with abnormalities that would potentially interfere
with later diagnosis of MVA induced myo/pericarditis.
As the aim of this post hoc analysis was to investigate incidental
ECG variations in a healthy African vaccine trial screening population,
we excluded participants from the analysis who met at least one of the
following criteria which could potentially lead to ECG abnormalities:
HIV infection, evidence of current of past cardiac or cardio-vascular
disease as assessed by medical history and physical examination, known
hypertension or conﬁrmed systolic blood pressure > 140/90 mm Hg,
known diabetes or conﬁrmed moderate or above hyperglycaemia,
severe anaemia (haemoglobin levels< 9.0 g/dL), and moderate or
above creatinine or ALT elevations to exclude signiﬁcant renal or
hepatic diseases. Severity grades were based on the DAIDS toxicity
table (Division of AIDS, Natl. Institutes of Health, Bethesda, MD) [24].
We included women with a positive pregnancy test into this analysis if
pregnancy was deemed to be at an early stage (ﬁrst trimester).
2.3. ECG Data Acquisition and Interpretation
ECGs were acquired on a MAC 1200 electrocardiograph (GE
Medical Systems) as supine 12-lead ECGs at 25 mm/s with 1 cm/mV.
Two trained study physicians at each site interpreted ECGs on paper. A
panel of two national and one international cardiologists reviewed the
interpretations to reach a ﬁnal consensus. As TaMoVac 01 was a safety
study, volunteers with pathological ECGs or variations that could
potentially interfere with the later interpretation of myo/pericarditis
were excluded from enrolment in the vaccine trial. Pathological ECGs
and variations leading to exclusion from the vaccine trial were deﬁned
as: (i) conduction disturbance such as complete left or right bundle
branch block or nonspeciﬁc intraventricular conduction disturbance
with QRS> 120 ms, AV block of any degree, or QTc prolongation
(> 440 ms), (ii) signiﬁcant repolarization (ST segment or T wave)
abnormality, (iii) signiﬁcant atrial or ventricular arrhythmia; frequent
atrial or ventricular ectopy, and (iv) ST-elevation consistent with
ischemia or evidence of past or evolving myocardial infarction.
In our post hoc analysis we assessed (i) the Sokolow-Lyon Index
with S in V1 plus R in V5 or V6 required to surpass 3.5 mV [25], and (ii)
the Cornell Index with S in V3 plus R in aVL required to surpass 2.0 mV
in women and 2.8 mV in men [26,27] to meet criteria for LVH. ST-
Elevation was recorded if there was an elevation of the QRS-ST junction
(J point) of≥0.1 mV or≥0.2 mV in at least one lead [14,28]. ERP was
deﬁned as an elevation of the QRS–ST junction by at least 0.1 mV in at
least two of the following leads: I, II, III, aVF, aVL, V4, V5 or V6 [29].
2.4. Data collection and statistical analysis
ECG, clinical and laboratory data were recorded in study speciﬁc
case report forms, double-entered into an SQL database, compared and
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corrected for data entry errors and then extracted for data analysis. The
following outcomes were considered during statistical analysis: ST-
elevations ≥0.1 mV and ≥0.2 mV, LVH as deﬁned by Sokolow-Lyon
and Cornell criteria and ERP. Comparisons of binary and continuous
variables between groups were performed using the Wilcoxon rank-sum
test. Repeated measures within the same individuals were performed
using McNemar's exact test. Poisson regression with robust variance
estimates was used to analyse associations of gender, age, body mass
index (BMI), and body height (as an indicator for cardiac size) with the
above outcome variables in univariate models, and in multivariate
models adjusted for gender and age. For all statistical tests an alpha
level of< 0.05 was used to deﬁne signiﬁcance. All statistical analyses
were performed using Stata statistics software (version 14, StataCorp,
College Station, TX, USA), graphs were drawn in MS Excel.
3. Results
For the TaMoVac01 trial, 508 volunteers underwent screening
procedures of whom 263 volunteers, who were not otherwise excluded,
received ECG assessments. During the 70 weeks of active follow-up, no
cardiac events were noted in the population enrolled in the vaccine
study. Of those 263 participants, six were excluded from this analysis
due to conditions that might lead to abnormal ECG readings. These
conditions were: prior heart disease in two, hypertension in two, HIV
infection in one, and signiﬁcant alcohol abuse in one participant,
respectively. Three females with positive pregnancy tests were kept in
the analysis as pregnancies were at early stages. Baseline characteristics
for the remaining 257 participants included in the analysis are shown in
Table 1. In brief, 63% of participants were males, the median age was
23 years, and the median BMI 21.7 kg/m2. Males were slightly but
signiﬁcantly older, taller, had a lower median BMI, had higher median
systolic blood pressure, and had lower median heart rate (within
normal ranges) as compared to females, respectively.
Overall positivity for LVH either deﬁned by SL or by Cornell criteria
was seen in 53 (20.6%) and 9 (3.5%) participants, respectively. ST-
elevation with a threshold of ≥0.1 mV and ≥0.2 mV was seen in 200
(77.8%) and 98 (38.1%) participants, respectively, and ERP was
detected in 60 (23.4%) participants. The prevalences of above outcomes
stratiﬁed by gender are shown in Fig. 1. Signiﬁcantly higher preva-
lences of LVH according to SL criteria, ST-elevations, and ERP were
detected in males. LVH according to Cornell criteria did not show a
signiﬁcant gender diﬀerence, however, a trend towards a higher
proportion was seen in females. As indicated above, the SL criteria
for LVH were more frequently positive than the Cornell criteria. This
was mainly due to the large diﬀerence between the prevalence of these
two criteria in males (30.3% versus 1.9%, p < 0.001), whereas
diﬀerences seen in females were not signiﬁcant (4.2% versus 6.3%,
p= 0.727).
In multivariate regression analyses adjusted for gender and age,
positive SL criteria were signiﬁcantly associated with male gender and
younger age, whereas lower BMI and increased body height were
signiﬁcantly associated with SL only in univariate analysis (Table 2). In
contrast, LVH according to Cornell criteria was signiﬁcantly associated
with younger age after adjusting for gender and age in multivariate
analysis, but not for gender, BMI, or body height in neither uni-nor
multivariate regression analysis. There were signiﬁcantly higher pro-
portions of concurrent ST segment elevations and ERP among partici-
pants with LVH as deﬁned by SL criteria that were not observed with
Cornell criteria. ST segment elevation and ERP were signiﬁcantly
associated with male gender in both, univariate and multivariate
analyses, and with greater body height in univariate analysis. Addi-
tionally, ST elevation was associated with lower BMI in univariate
analysis. An association with younger age was shown in multivariate
analysis for ST elevations ≥0.2 mV. Of note, ERP in association with
ST-elevation ≥0.2 mV was detected in 40 (15.6%) participants. 20
(7.8%) of those participants demonstrated ERP in association with ST-
elevation ≥0.2 mV without high QRS amplitudes as indicated by
positive SL criteria, which could potentially indicate a higher risk for
catastrophic arrhythmias.
An ECG pattern of a participant with positive LVH SL criteria in
combination with ST-elevation and evidence of ERP with notching of
the J-point is shown in Fig. 2A and without positive LVH criteria but ST-
elevation in Fig. 2B, which has been referred as a typical “male
pattern”. In Fig. 2C an example of a participant with ERP is shown
with ST-elevation in the limb leads and slurring of the QRS-ST junction
which is referred to as a J-wave.
ECG ﬁndings leading to ineligibility during the screening period of
the vaccine trial were detected in 58/263 (22.1%) volunteers with ECG
assessments, and 41 (15.6%) volunteers were screened out only due to
ECG abnormalities without meeting other ineligibility criteria. Apart
from above described ST-elevation, ERP and left ventricular hypertro-
phy criteria, other ﬁndings leading to ineligibility were abnormal T-
wave inversion (N= 10), Right Bundle Branch Blocks (N= 6) includ-
ing one suspected case with a Brugada syndrome, Left Bundle Branch
Block (N= 1), higher grade AV-Blocks (N= 2) and ectopic atrial
rhythms (N= 2).
4. Discussion
There was an overall high rate of screen outs in our MVA vector
containing HIV vaccine trial due to ECG ﬁndings in young and
otherwise clinically healthy volunteers in Tanzania. The most com-
monly encountered ECG abnormalities were signs of left ventricular
hypertrophy, ST segment elevation and ERP. Across all ECG abnorm-
alities analysed, male gender and younger age were the predominant
factors that inﬂuenced the occurrence of most probably clinically
insigniﬁcant ECG variations. Factors related to body shape and fat
distribution such as lower BMI or greater body height were associated
with most abnormalities in univariate regression analysis.
Sokolow Lyon criteria presumably over-diagnosed left ventricular
hypertrophy in males as compared to the Cornell criteria (30% vs 2%).
In contrast, both LVH criteria were positive in females in about one out
of twenty individuals and no signiﬁcant diﬀerence in the prevalence
between both criteria was seen. Similar results including gender
diﬀerences with predominance in males presenting positive Sokolow
Lyon criteria have been described from diﬀerent studies conducted in
Africa supporting the evidence that Cornell criteria in African popula-
Table 1
Volunteer characteristics and prevalence of left ventricular hypertrophy (LVH) by
Sokolow Lyon and Cornell criteria, ST-elevation in any lead of ≥0.1 mV or ≥0.2 mV,
or for early repolarization (ERB) by gender.
Total
N= 257
Male
N= 162
Female
N= 95
p value#
Age (years), median
(IQR)
23 (20 to
28)
24 (20 to
29)
21 (19 to
26)
0.040
BMI (kg/m2), median
(IQR)
21.7 (19.8 to
24.1)
21.4 (19.6 to
23.3)
23.1 (20.2
to 25.6)
0.002
Height (cm), median
(IQR)
164 (158 to
170)
168 (163 to
173)
157 (152 to
160)
< 0.001
BP systolic (mm Hg),
median (IQR)
119 (110 to
121)
120 (110 to
125)
110 (104 to
120)
< 0.001
BP diastolic (mm Hg),
median (IQR)
71 (69 to
80)
72 (69 to
80)
70 (66 to
80)
0.367
Heart Rate (beats/min),
median (IQR)
67 (57 to
73)
62 (54 to
69)
72 (66 to
79)
< 0.001
LVH by Sokolow Lyon
Index
53 (20.6%) 49 (30.3%) 4 (4.2%) < 0.001
LVH by Cornell Index 9 (3.5%) 3 (1.9%) 6 (6.3%) 0.061
ST elevation ≥0.1 mV 200 (77.8%) 151 (93.2%) 49 (51.6%) < 0.001
ST elevation ≥0.2 mV 98 (38.1%) 91 (56.2%) 7 (7.4%) < 0.001
Early repolarization 60 (23.4%) 50 (30.9%) 10 (10.5%) < 0.001
# p-value of Wilcoxon rank-sum test for comparisons of males versus females.
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tions should preferentially be used and are less likely to suggest LVH
[8,9,10,11,12].
Sokolow Lyon criteria have mainly been developed on white
populations and reasons why these criteria are more likely to result
into false positive LVH diagnosis in African origin populations have
been attributed to socioeconomic and nutritional factors, diﬀerences in
body shape, fat distributions, and physiological diﬀerences in ventricle
sizes [30,31]. Higher QRS amplitudes in older populations of African-
Americans as compared to white populations have been described for
both men and women despite comparable left ventricular mass as
measured by echocardiography, indicating racial diﬀerences which
were partly explained by smaller lateral chest diameter in individuals
of African origin [32]. As reviewed by Fraley et al. [33], higher BMI or
obesity is known to lead to lower QRS voltages eﬀecting especially ECG
LVH criteria that rely on left or right precordial voltage such as the
Sokolow Lyon Index. This is likely attributed to variable degrees of
chest wall and epicardial fat which may result in increased distances of
chest leads to the heart surface. Furthermore, diﬀerence in absolute
cardiac size might explain gender speciﬁc diﬀerences in QRS ampli-
tudes and body height has been described as a marker which correlates
with left ventricular mass [34] impacting the prevalence of positive
Sokolow Lyon criteria. High prevalence of positive Sokolow Lyon
criteria especially in young and slender males in our analysis are
therefore likely a result of lower BMI associated with younger age,
racial characteristics of small lateral chest diameter, gender diﬀerences
in cardiac size and chest wall impedance because of subcutaneous
breast tissue, and lean body mass. As age was one of the predominant
variables aﬀecting both positive Sokolow Lyon and Cornell criteria,
other factors such as age related myocyte atrophy might have already
aﬀected ECG readouts in our young population.
A high predominance of ST-elevation and J-point amplitudes
≥0.1 mV has been described as a typical male pattern in contrast to
a female pattern which is more often represented with a J-point
amplitude< 0.1 mV. ST-elevations have been associated with younger
age and male gender in other studies, with proportions comparable to
the ones found in our cohort [13,14]. Furthermore, signiﬁcant diﬀer-
Fig. 1. Proportion of volunteers with positive ECG for left ventricular hypertrophy (LVH),
ST-elevations and early repolarization by gender.
Table 2
Factors associated with left ventricular hypertrophy (LVH) by Sokolow Lyon and Cornell criteria, ST-elevation in any lead of≥0.1 mV or≥0.2 mV, or for early repolarization (ERP) in
univariate analysis and multivariate analysis adjusted for gender and age. The signiﬁcance of bold is p < 0.001.
Univariate analysis
Total population (N= 257)
Multivariate analysis
(adjusted for gender, age)
Total population (N= 257)
Univariate analysis
Males (N= 162)
Univariate analysis
Females (N= 95)
LVH (Sokolow Lyon) PR (95% CI) p value PR (95% CI) p value PR (95% CI) p value PR (95% CI) p value
Male versus female 7.18 (2.67 to 19.32) < 0.001 7.84 (2.92 to 21.06) < 0.001 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Age, per 5 years increase 0.76 (0.61 to 0.96) 0.020 0.70 (0.56 to 0.88) 0.002 0.70 (0.55 to 0.89) 0.003 0.75 (0.34 to 1.61) 0.456
BMI, per kg/m2 increase 0.90 (0.84 to 0.97) 0.004 0.97 (0.89 to 1.05) 0.423 0.93 (0.87 to 1.01) 0.075 0.91 (0.67 to 1.23) 0.529
Height, per 5 cm increase 1.32 (1.19 to 1.46) < 0.001 1.12 (0.96 to 1.31) 0.145 1.05 (0.89 to 1.23) 0.602 2.06 (1.58 to 2.70) < 0.001
ST elevation ≥0.1 mV 7.27 (1.82 to 29.02) 0.005 3.25 (0.78 to 13.50) 0.105 3.50 (0.53 to 23.12) 0.194 2.81 (0.30 to 26.43) 0.365
ST elevation ≥0.2 mV 4.99 (2.81 to 8.86) < 0.001 2.76 (1.53 to 4.98) 0.001 3.47 (1.80 to 6.68) < 0.001 ⁎⁎ ⁎⁎
Early repolarization 3.16 (2.00 to 4.98) < 0.001 2.57 (1.71 to 3.87) < 0.001 2.53 (1.61 to 3.98) < 0.001 ⁎⁎ ⁎⁎
LVH (Cornell)
Male versus female 0.29 (0.07 to 1.15) 0.078 0.35 (0.09 to 1.41) 0.139 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Age, per 5 years increase 0.41 (0.23 to 0.72) 0.002 0.44 (0.24 to 0.82) 0.010 0.17 (0.04 to 0.74) 0.018 0.61 (0.36 to 1.04) 0.072
BMI, per kg/m2 increase 1.00 (0.82 to 1.20) 0.962 1.02 (0.82 to 1.24) 0.868 0.90 (0.60 to 1.34) 0.598 0.98 (0.81 to 1.19) 0.840
Height, per 5 cm increase 0.79 (0.52 to 1.19) 0.253 0.94 (0.49 to 1.77) 0.838 0.55 (0.31 to 0.99) 0.045 1.23 (0.60 to 2.55) 0.572
ST elevation ≥0.1 mV 2.28 (0.29 to 17.92) 0.443 4.50 (0.56 to 36.15) 0.158 ⁎⁎ ⁎⁎ 4.69 (1.56 to 39.11) 0.153
ST elevation ≥0.2 mV 1.30 (0.36 to 4.73) 0.693 3.86 (0.53 to 28.06) 0.181 1.56 (0.14 to 17.00) 0.715 6.29 (1.37 to 28.76) 0.018
Early repolarization⁎ – – – – – – – –
ST-elevation≥ 0.1 mV
Male versus female 1.81 (1.48 to 2.21) < 0.001 1.81 (1.48 to 2.22) < 0.001 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Age, per 5 years increase 1.01 (0.96 to 1.08) 0.628 0.99 (0.94 to 1.04) 0.644 1.01 (0.96 to 1.05) 0.740 0.92 (0.76 to 1.13) 0.428
BMI, per kg/m2 increase 0.98 (0.95 to 1.00) 0.027 0.99 (0.97 to 1.01) 0.331 0.99 (0.98 to 1.01) 0.495 0.98 (0.94 to 1.03) 0.456
Height, per 5 cm increase 1.10 (1.06 to 1.15) < 0.001 1.02 (0.98 to 1.06) 0.278 0.99 (0.96 to 1.02) 0.343 1.15 (1.02 to 1.29) 0.018
ST-elevation≥ 0.2 mV
Male versus female 7.62 (3.68 to 15.78) < 0.001 8.05 (3.89 to 16.67) < 0.001 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Age, per 5 years increase 0.87 (0.75 to 1.01) 0.075 0.81 (0.71 to 0.93) 0.003 0.80 (0.70 to 0.93) 0.003 0.93 (0.54 to 1.59) 0.781
BMI, per kg/m2 increase 0.95 (0.91 to 1.00) 0.041 1.01 (0.97 to 1.07) 0.486 0.98 (0.94 to 1.03) 0.433 1.04 (0.90 to 1.21) 0.604
Height, per 5 cm increase 1.20 (1.11 to 1.30) < 0.001 0.97 (0.89 to 1.06) 0.469 0.97 (0.88 to 1.06) 0.507 0.83 (0.58 to 1.21) 0.334
Early repolarization
Male versus female 2.93 (1.56 to 5.51) 0.001 2.86 (1.52 to 5.38) 0.001 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Age, per 5 years increase 1.14 (0.96 to 1.35) 0.123 1.10 (0.93 to 1.30) 0.281 1.10 (0.91 to 1.32) 0.339 1.11 (0.74 to 1.68) 0.616
BMI, per kg/m2 increase 0.97 (0.91 to 1.03) 0.321 0.98 (0.92 to 1.05) 0.589 0.99 (0.92 to 1.07) 0.851 1.00 (0.91 to 1.09) 0.962
Height, per 5 cm increase 1.18 (1.05 to 1.31) 0.004 1.03 (0.90 to 1.19) 0.664 1.07 (0.92 to 1.24) 0.401 0.86 (0.59 to 1.26) 0.441
PR = prevalence ratio
⁎ No data as no co-prevalence of LVH by Cornell with early repolarization.
⁎⁎ Cannot be estimated since outcome does not vary.
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ences in ST elevations among ethnic groups have been reported and
were lowest in white populations as compared to African Americans
who had the greatest ST elevations in leads I and V3 to V6 [35]. In the
same study, BMI was inversely associated with ST-elevations which was
also seen in our analysis. As we found a high co-variation of high QRS
amplitudes as seen by positive SL criteria and ST-elevation, a possible
reason for both ﬁndings is an increase in transmission of electrical
currents from the heart to the electrodes secondary to less fatty tissue
and related decreased distance/impedance. A pattern of ST-elevation
consistent with positive criteria for ERP was hence predominantly
found in young males in our analysis as well.
As recently reviewed by Ali et al. [15], the prevalence of ERP varies
between 3% and 24% in the general population depending on the
population studied with the highest prevalence seen in young males of
African heritage and athletes [17,18]. As in our study population, ERP
is usually incidentally diagnosed and considered benign with a negli-
gible likelihood for developing catastrophic arrhythmias if asympto-
matic, found in younger age groups, and co-prevalent with LVH on ECG
[19,36,37,38,39]. On the other hand, individuals with ERP patterns
associated with ST-elevation of ≥0.2 mV have been discussed to be of
greater risk for fatal arrhythmias [40,41,42]. In our analysis this was
found in 7.8% in the absence of high QRS amplitudes - possibly
indicating a bias in transmission of electrical currents due to decreased
chest wall impedance. The potential prognostic implications of these
ECG patterns for fatal arrhythmias in a predominantly young and male
African population would need to be determined.
A limitation of our analysis is that the study was not primarily
designed to analyse ECG abnormalities and no cardiologic investiga-
tions other than clinical assessments and ECGs were performed. In this
respect, no echocardiography or troponin evaluations were performed
to support cardiac health or exclude morphologically abnormal cardiac
conditions. As participants were of young age and clinically healthy by
history and clinical examination, we feel that underlying cardiologic
disease is unlikely in the vast majority of the individuals. No automated
system was used to better standardize ECG analyses and all measure-
ments were performed manually. As all ECGs were interpreted by at
least two independent physicians and reviewed by a panel of experi-
enced cardiologists, the likelihood of misinterpretations has been kept
to a minimum.
In conclusion, high prevalence of LVH as deﬁned by SL criteria,
often associated with ST elevation and early repolarization predomi-
nantly seen in young, male, and clinically healthy Africans is a common
ﬁnding that needs to be taken into consideration when screening for
disease or eligibility criteria for potentially cardiotoxic investigational
products. In the case of our MVA containing vaccine trial, ECG deﬁned
ineligibility was noted in at least 22.1% of the screening population
who received ECG assessments. Screen outs due to ECG ﬁndings
(11.3%) were reported for a North American MVA-containing vaccine
trial in a predominantly Caucasian population [43]. The deﬁnitions for
a “normal” ECG are largely based on references from Caucasian
populations and do not necessarily translate into ECG ﬁndings in an
African population. Investigations that evaluate diﬀerences in ECGs by
ethnicity commonly refer to African-Americans or older African popu-
lations and are often associated with cardiovascular disease. Conver-
sely, our data add to the scarcely available reports of ECG ﬁndings in
young and healthy Africans. Main factors contributing to abnormal ECG
patterns are likely caused by morphological chest characteristics and
resulting distances of ECG electrodes to the heart in young African
males. In African populations, Cornell criteria should be preferred for
the interpretation of LVH by ECG as they appear to be less inﬂuenced by
anthropomorphic variables and gender. The impact of ERP with ST-
elevations ≥0.2 mV, especially in the absence of concomitant positive
SL criteria as a risk factor for fatal arrhythmias needs to be further
determined in young African populations.
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